Cancer stem cells in cutaneous melanoma

Expert Review of Dermatology

Volumn 4, Issue 3, 2009, Pages 225-235

  Wouters, Jasper ^a,b   Vankelecom, Hugo ^b   van den Oord, Joost ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Cancer stem cell; Chemotherapy; Melanocyte; Melanoma; Side population

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CD20 ANTIGEN; MULTIDRUG RESISTANCE PROTEIN 5; NESTIN; TOXIC SUBSTANCE;

CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CELL HETEROGENEITY; CELL POPULATION; DRUG TARGETING; HUMAN; MELANOCYTE; MELANOMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; STEM CELL; TARGET CELL; TUMOR GROWTH;

EID: 69949166565     PISSN: 17469872     EISSN: None     Source Type: Journal    
DOI: 10.1586/edm.09.17     Document Type: Review

References (86)

1. Miller AJ, Mihm MC Jr. Melanoma. N. Engl. J. Med. 355(1), 51-65 (2006).
2. Garbe C, Blum A. Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol. Appl. Skin Physiol. 14(5), 280-290 (2001).
3. Eide MJ, Weinstock MA. Association of UV index, latitude, and melanoma incidence in nonwhite populations - US Surveillance, Epidemiology, and End Results (SEER) Program, 1992 to 2001. Arch. Dermatol. 141(4), 477-481 (2005).
4. Chang YM, Barrett JH, Bishop DT et al. Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls. Int. J. Epidemiol. (2009) (Epub ahead of print).
5. Cancer Facts and Figures 2008. American Cancer Society, Atlanta, GA, USA (2008).
6. Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br. J. Dermatol. 150(2), 179-185 (2004).
7. Schaffer JV, Rigel DS, Kopf AW, Bolognia JL. Cutaneous melanoma - past, present, and future. J. Am. Acad. Dermatol. 51(1 Suppl.), S65-S69 (2004).
8. Wang SQ, Halpern AC. Management of cutaneous melanoma: a public health and individual patient care perspective. Adv. Dermatol. 23, 81-98 (2007).
9. Aloia TA, Gershenwald JE. Management of early-stage cutaneous melanoma. Curr. Probl. Surg. 42(7), 460-534 (2005).
10. Buzaid AC. Management of metastatic cutaneous melanoma. Oncology (Williston Park) 18(11), 1443-1450; discussion 1457-1449 (2004).
11. Agar N, Young AR. Melanogenesis: a photoprotective response to DNA damage? Mutat. Res. 571(1-2), 121-132 (2005).
12. Meredith P, Riesz J. Radiative relaxation quantum yields for synthetic eumelanin. Photochem. Photobiol. 79(2), 211-216 (2004).
13. Brenner M, Hearing VJ. The protective role of melanin against UV damage in human skin. Photochem. Photobiol. 84(3), 539-549 (2008).
14. Kavak A, Akcan Y, Korkmaz U. Hair repigmentation in a hepatitis C patient treated with interferon and ribavirin. Dermatology 211(2), 171-172 (2005).
15. Na GY, Paek SH, Park BC et al. Isolation and characterization of outer root sheath melanocytes of human hair follicles. Br. J. Dermatol. 155(5), 902-909 (2006).
16. Moriyama M, Osawa M, Mak SS et al. Notch signaling via Hes1 transcription factor maintains survival of melanoblasts and melanocyte stem cells. J. Cell Biol. 173(3), 333-339 (2006).
17. Levy C, Khaled M, Fisher DE. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol. Med. 12(9), 406-414 (2006).
18. Lekmine F, Chang CK, Sethakorn N, Das Gupta TK, Salti GI. Role of microphthalmia transcription factor (Mitf) in melanoma differentiation. Biochem. Biophys. Res. Commun. 354(3), 830-835 (2007).
19. Murisier F, Guichard S, Beermann F. The tyrosinase enhancer is activated by Sox10 and Mitf in mouse melanocytes. Pigment Cell Res. 20(3), 173-184 (2007).
20. Wegner M. Secrets to a healthy Sox life: lessons for melanocytes. Pigment Cell Res. 18(2), 74-85 (2005).
21. Lang D, Epstein JA. Sox10 and Pax3 physically interact to mediate activation of a conserved c-RET enhancer. Hum. Mol. Genet. 12(8), 937-945 (2003).
22. Lang D, Lu MM, Huang L et al. Pax3 functions at a nodal point in melanocyte stem cell differentiation. Nature 433(7028), 884-887 (2005).
23. Yang G, Li Y, Nishimura EK et al. Inhibition of PAX3 by TGF-β modulates melanocyte viability. Mol. Cell 32(4), 554-563 (2008).
24. Kubic JD, Young KP, Plummer RS, Ludvik AE, Lang D. Pigmentation PAX-ways: the role of Pax3 in melanogenesis, melanocyte stem cell maintenance, and disease. Pigment Cell Melanoma Res. 21(6), 627-645 (2008).
25. Nishikawa S, Osawa M. Generating quiescent stem cells. Pigment Cell Res. 20(4), 263-270 (2007).
26. Osawa M, Egawa G, Mak SS et al. Molecular characterization of melanocyte stem cells in their niche. Development 132(24), 5589-5599 (2005).
27. Morris RJ, Liu Y, Marles L et al. Capturing and profiling adult hair follicle stem cells. Nat. Biotechnol. 22(4), 411-417 (2004).
28. Tumbar T, Guasch G, Greco V et al. Defining the epithelial stem cell niche in skin. Science 303(5656), 359-363 (2004).
29. Vance KW, Goding CR. The transcription network regulating melanocyte development and melanoma. Pigment Cell Res. 17(4), 318-325 (2004).
30. Garraway LA, Widlund HR, Rubin MA et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436(7047), 117-122 (2005).
31. Carreira S, Goodall J, Denat L et al. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. 20(24), 3426-3439 (2006).
32. Larue L, Delmas V. The WNT/B-catenin pathway in melanoma. Front Biosci. 11, 733-742 (2006).
33. Lin YC, You L, Xu Z et al. Wnt inhibitory factor-1 gene transfer inhibits melanoma cell growth. Hum. Gene Ther. 18(4), 379-386 (2007).
34. Zhuang L, Lee CS, Scolyer RA et al. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod. Pathol. 20(4), 416-426 (2007).
35. Weeraratna AT. A Wnt-er wonderland - the complexity of Wnt signaling in melanoma. Cancer Metastasis Rev. 24(2), 237-250 (2005).
36. Wellbrock C, Rana S, Paterson H et al. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS ONE 3(7), e2734 (2008).
37. Malanchi I, Peinado H, Kassen D et al. Cutaneous cancer stem cell maintenance is dependent on β-catenin signalling. Nature 452(7187), 650-653 (2008).
38. Watt FM, Collins CA. Role of β-catenin in epidermal stem cell expansion, lineage selection, and cancer. Cold Spring Harb. Symp. Quant. Biol. (2008) (Epub ahead of print).
39. Wang Z, Li Y, Banerjee S, Sarkar FH. Emerging role of Notch in stem cells and cancer. Cancer Lett. 279(1), 8-12 (2008).
40. Chien AJ, Moore EC, Lonsdorf AS et al. Activated Wnt/ β-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc. Natl Acad. Sci. USA 106(4), 1193-1198 (2009).
41. Quintana E, Shackleton M, Sabel MS et al. Efficient tumour formation by single human melanoma cells. Nature 456(7222), 593-598 (2008).
42. Dick JE. Looking ahead in cancer stem cell research. Nat. Biotechnol. 27(1), 44-46 (2009).
43. Clarke MF, Dick JE, Dirks PB et al. Cancer stem cells - perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 66(19), 9339-9344 (2006).
44. Eaves CJ. Cancer stem cells: here, there, everywhere? Nature 456(7222), 581-582 (2008).
45. Bongiorno MR, Doukaki S, Malleo F, Arico M. Identification of progenitor cancer stem cell in lentigo maligna melanoma. Dermatol. Ther. 21(Suppl. 1), S1-S5 (2008).
46. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea - a paradigm shift. Cancer Res. 66(4), 1883-1890 (2006).
47. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730-737 (1997).
48. + cells with cancer stem cell characteristics. Breast Cancer Res. 10(1), R10 (2008).
49. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature 445(7123), 111-115 (2007).
50. + population efficiently enriches colon cancer initiating cells. Ann. Surg. Oncol. 15(10), 2927-2933 (2008).
51. Vander Griend DJ, Karthaus WL, Dalrymple S et al. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res. 68(23), 9703-9711 (2008).
52. Kelly K, Yin JJ. Prostate cancer and metastasis initiating stem cells. Cell Res. 18(5), 528-537 (2008).
53. Zhang S, Balch C, Chan MW et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 68(11), 4311-4320 (2008).
54. Li C, Heidt DG, Dalerba P et al. Identification of pancreatic cancer stem cells. Cancer Res. 67(3), 1030-1037 (2007).
55. Kiel MJ, He S, Ashkenazi R et al. Haematopoietic stem cells do not asymmetrically segregate chromosomes or retain BrdU. Nature 449(7159), 238-242 (2007).
56. Fang D, Nguyen TK, Leishear K et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 65(20), 9328-9337 (2005).
57. Frank NY, Margaryan A, Huang Y et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 65(10), 4320-4333 (2005).
58. Grichnik JM, Burch JA, Schulteis RD et al. Melanoma, a tumor based on a mutant stem cell? J. Invest. Dermatol. 126(1), 142-153 (2006).
59. Klein WM, Wu BP, Zhao S et al. Increased expression of stem cell markers in malignant melanoma. Mod. Pathol. 20(1), 102-107 (2007).
60. Monzani E, Facchetti F, Galmozzi E et al. Mela noma contains CD133 and ABCG2 posi tive cells with enhanced tumour igenic pot ential. Eur. J. Cancer 43(5), 935-946 (2007).
61. Mihic-Probst D, Kuster A, Kilgus S et al. Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma. Int. J. Cancer 121(8), 1764-1770 (2007).
62. Sigalotti L, Covre A, Zabierowski S et al. Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status. J. Cell. Physiol. 215(2), 287-291 (2008).
63. Schatton T, Murphy GF, Frank NY et al. Identification of cells initiating human melanomas. Nature 451(7176), 345-349 (2008).
64. Keshet GI, Goldstein I, Itzhaki O et al. MDR1 expression identifies human melanoma stem cells. Biochem. Biophys. Res. Commun. 368(4), 930-936 (2008).
65. Cook AL, Donatien PD, Smith AG et al. Human melanoblasts in culture: expression of BRN2 and synergistic regulation by fibroblast growth factor-2, stem cell factor, and endothelin-3. J. Invest. Dermatol. 121(5), 1150-1159 (2003).
66. Strizzi L, Abbott DE, Salomon DS, Hendrix MJ. Potential for cripto-1 in defining stem cell-like characteristics in human malignant melanoma. Cell Cycle 7(13), 1931-1935 (2008).
67. Kleinman HK, Martin GR. Matrigel: basement membrane matrix with biological activity. Semin. Cancer Biol. 15(5), 378-386 (2005).
68. Zabierowski SE, Herlyn M. Learning the ABCs of melanoma-initiating cells. Cancer Cell 13(3), 185-187 (2008).
69. Zhou J, Wang CY, Liu T et al. Persistence of side population cells with high drug efflux capacity in pancreatic cancer. World J. Gastroenterol. 14(6), 925-930 (2008).
70. Dean M. ABC transporters, drug resistance, and cancer stem cells. J. Mammary Gland Biol. Neoplasia 14(1), 3-9 (2009).
71. Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv. Drug Deliv. Rev. 61(1), 26-33 (2009).
72. - cancer cells are similarly tumorigenic. Cancer Res. 65(14), 6207-6219 (2005).
73. Robey RW, Polgar O, Deeken J, To KW, Bates SE. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev. 26(1), 39-57 (2007).
74. Hirschmann-Jax C, Foster AE, Wulf GG et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc. Natl Acad. Sci. USA 101(39), 14228-14233 (2004).
75. Smalley KS, Brafford P, Haass NK et al. Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. Am. J. Pathol. 166(5), 1541-1554 (2005).
76. Feldmann G, Dhara S, Fendrich V et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 67(5), 2187-2196 (2007).
77. Balint K, Xiao M, Pinnix CC et al. Activation of Notch1 signaling is required for β-catenin-mediated human primary melanoma progression. J. Clin. Invest. 115(11), 3166-3176 (2005).
78. Liu ZJ, Xiao M, Balint K et al. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/ phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res. 66(8), 4182-4190 (2006).
79. Stecca B, Mas C, Clement V et al. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc. Natl Acad. Sci. USA 104(14), 5895-5900 (2007).
80. Qin JZ, Stennett L, Bacon P et al. p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. Mol. Cancer Ther. 3(8), 895-902 (2004).
81. Hamai A, Meslin F, Benlalam H et al. ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathway. Cancer Res. 68(23), 9854-9864 (2008).
82. Rappa G, Fodstad O, Lorico A. The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 26(12), 3008-3017 (2008).
83. Yi JM, Tsai HC, Glockner SC et al. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res. 68(19), 8094-8103 (2008).
84. Jaksch M, Munera J, Bajpai R, Terskikh A, Oshima RG. Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines. Cancer Res. 68(19), 7882-7886 (2008).
85. Winnepenninckx V, Lazar V, Michiels S et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J. Natl Cancer Inst. 98(7), 472-482 (2006).
86. Kauffmann A, Rosselli F, Lazar V et al. High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene 27(5), 565-573 (2008).